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A B S T R A C T
Introduction: Non-small-cell lung cancer exhibits a range of transcriptional and epigenetic patterns that not only
define distinct phenotypes, but may also govern immune related genes, which have a major impact on survival.
Methods: We used open-source RNA expression and DNA methylation data of the Cancer Genome Atlas with
matched non-cancerous tissue to evaluate whether these pretreatment molecular patterns also influenced genes
related to the immune system and overall survival.
Results: The distinction between lung adenocarcinoma and squamous cell carcinoma are determined by 1083
conserved methylation loci and RNA expression of 203 genes which differ for> 80 % of patients between the
two subtypes. Using the RNA expression profiles of 6 genes, more than 95 % of patients could be correctly
classified as having either adeno or squamous cell lung cancer. Comparing tumor tissue with matched normal
tissue, no differences in RNA expression were found for costimulatory and co-inhibitory genes, nor genes in-
volved in cytokine release. However, genes involved in antigen presentation had a lower expression and a wider
distribution in tumor tissue.
Discussion: Only a small number of genes, influenced by DNA methylation, determine the lung cancer subtype.
The antigen presentation of cancer cells is dysfunctional, while other T cell immune functions appear to remain
intact.
1. Introduction
Smoking induced lung cancer has a large number of DNA mutations
while other environmental factors such as air pollution may cause a
different distribution in DNA mutations, often observed in non-smokers
in genes like EGFR, BRAF, HER2 and ALK [1]. Lung cancer is
traditionally subdivided into small-cell lung cancer and non-small-cell
lung cancer (NSCLC) with the latter being divided into two main sub-
types, adenocarcinoma and squamous cell carcinoma (SCC).
It is known that DNA methylation is affected by age, smoking,
emphysema and histological subtype [2]. Changes in the methylation
pattern affects RNA expression, leading not only to different
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phenotypes, but also to a different effect on the immune activation. This
may not only be reflected in the expression of human leukocyte antigen
(HLA) or PD-L1 on tumor cells, but also in the tumor microenviron-
ment. The Cancer Genome Atlas group (TCGA) performed molecular
studies on lung adenocarcinoma and SCC identifying driver oncogenes
and loss-of-function mutations in the HLA-A class I major histo-
compatibility gene [3,4]. Molecular classification approaches were
made by clustering phenotypes on different platforms [5]. In a more
recent study, a “cluster-of-clusters” analytic approach on differential
DNA expression showed three distinct subtypes within SCC and six
within adenocarcinomas [6]. Three of the adenocarcinoma subtypes
had high expression of several immune related genes including PD-L1,
PD-L2, CD3 and CD8.
To date, the role of epigenetic modifications in relation to tumor
responses in NSCLC remains to be clarified. Global DNA hypomethy-
lation at repeated sequences has been identified in tumor cells in
combination with DNA hypermethylation at specific loci [7]. CpG di-
nucleotides are highly represented in repeated sequences of the genome
(LINE, SINE) and in the promotor regions of about 65 % of the human
genome and it is suggested that these play a role in regulation of gene
expression. Biopsies of both adenocarcinoma and SCC show differences
in methylation and in immune infiltrate [8]. Although their tumor re-
sponse to checkpoint inhibitors is similar (1 year progression-free sur-
vival of 21 % and 19 % for respectively SCC and non-SCC in the
Checkmate studies), different determinants driving tumor response and
resistance may be involved [9]. We hypothesized firstly, that a clear
separation based on DNA methylation and RNA expression can be made
between the NSCLC subtypes, and secondly, that methylation controls
immune modulating genes in the tumor DNA and tumor-intrinsic de-
fects must be present.
2. Results
2.1. Methylation in NSCLC
We used 1024 unique patients from NSCLC TCGA datasets. Based on
DNA methylation a PCA analysis appeared to be capable of separating
adenocarcinoma and SCC (Fig. 1a). The prediction model based on the
PCA outcomes correctly identified all but one of the included patients as
either adenocarcinoma or SCC. Importantly, stratification for high and
low purity (indicated as the proportion of tumor cell content) of the
processed samples did not influence the findings. Remarkably, of all
methylation probes with a ks-score ≥0.95, the mean corrected differ-
ences ranged from +0.02 to +0.15 (scale -1 - +1), implicating a very
small variation in methylation for these highly conserved loci in both
phenotypes and a consistent stronger methylation of adenocarcinoma
compared to SCC (Fig. 2).
After we observed significant differences in methylation probe dis-
tribution between the subtypes, we continued with a best split analysis.
The algorithm identified 1083 methylation probes (out of a total of
485,577 probes) which individually could be used to correctly classify
at least 85 % of patients. Next, we looked into the chromosomal posi-
tion of the different methylated probes. An even distribution along the
genome was determined at increasingly stringent ks-scores (Fig. 3a,b
and Extended Data Table 1).
The higher ks-score indicates a better separability between histo-
logic subtypes (Supplementary Information). The methylation pattern
for each chromosome characterized by individual probes with ks-score
≥ 95 % was distributed over all chromosomes except the X-chromo-
some. Probes with a high ks-score over 97 % for separability re-
presented conserved methylated loci that preserve the difference be-
tween phenotypes.
To address morphological differences between adenocarcinoma and
SCC based on DNA methylation, an enrichment analysis was performed
on the gene level based on the methylation probes that are most distinct
for phenotype (ks-score> 0.95; n = 2101 mapped genes). Remarkably,
these and other genes showed a low methylation rate compared to
normal tissue. The main canonical pathways that are most distinct for
NSCLC subtypes are DNA repair pathways (Extended Data Fig. 1).
However, based on the relative methylation of these genes, mechanisms
involved in response to the category “viral infections” (z-score 10.7,
p< 0.001;) were more activated in SCC compared to adenocarcinoma,
whereas mechanisms involved in cell death (z-score -17.8, p< 0.001)
were inhibited. Central genes involved in “viral infection” that are
found to be differential in SCC compared to adenocarcinoma include
IRF3, NFKB1, RELA (also known as NFKB3), STAT3, SRPK1 and TRIM.
2.2. Expression in NSCLC
We next aimed to investigate to what extent methylation influences
RNA expression levels. We observed that DNA methylation explains
approximately 40–55 % of the inversely correlated variation in the RNA
expression. This percentage, however, is not only dependent on the β-
value level that would biologically lead to effective epigenetic gene
suppression, but also on the correlation between gene expression and
methylation (Fig. 4e). Approximately 60 % of methylation probes
(different to the random 50 %) are inversely correlated with RNA ex-
pression by selecting only those methylation probes that are assumed to
have an epigenetic suppressive effect (average β-value>0.25) on DNA
transcription and with a significant correlation (correlation coeffi-
cient> 0.5 or< -0.5). Of note, methylation probes with a negative,
positive, or no relationship with gene expression could be determined
as illustrated in Fig. 4b–d (Supplementary information, sub 5). In
general, genes that were heavily methylated showed a lower RNA ex-
pression than genes that had a moderate or low methylation rate.
Unsupervised principal component analysis of the transcriptome led
to a slightly less accurate separation of NSCLC phenotypes (Fig. 1b)
than that based on DNA methylation data (Fig. 1a). Comparing tumor
with non-cancerous tissue confirms that the RNA expression pattern is
specific for NSCLC (Fig. 1b). The best split analysis on RNA data
identified 203 genes, of which the expression was different in 85 % of
cases between SCC and adenocarcinoma. Of these, differences in RNA
expression of five genes (KRT5, DSC3, DSG3, TP63, CALML3), and one
miRNA (MIR205HG) combined could separate both subtypes with an
accuracy of 95 %.
2.3. Bilevel molecular analysis in NSCLC
We selected the top 500 methylation probes with their corre-
sponding genes and the top 500 genes based on RNA expression and
found an overlap of 41 genes related to the separation of the NSCLC
phenotypes based on both DNA methylation and RNA expression
(Extended Data Table 2). Gene enrichment analysis by Ingenuity
Pathway Analysis revealed that TP63 was an important upstream reg-
ulator, with elevated expression in SCC compared to adenocarcinoma.
Target molecules of TP63 in the list of 41 genes included CSTA, SNAI2,
DST, ACTL6A, KRT7 and the miRNA MIR205HG, and their expression
was in the same predicted direction as the TP63 activation in SCC.
2.4. Immune modulating genes and methylation
As expected, methylation was inversely correlated for most methy-
lation probes, e.g. higher level of HLA-B, TAP1, CD2 methylation leads
to lower RNA expression (Fig. 4a). Of note, none of the 1083 methy-
lation probes identified by the best split analysis for histological sub-
type included any of the selected immune related genes.
We performed a principal component analysis including all RNA
expressing genes and determined the weight of each component of
immune modulatory gene groups: T cell co-inhibitory (COINHIB), T cell
co-stimulator (COSTIM), T cell antigen presentation (AGPRES) and T
cell cytokines/chemokines (CYTOCHEM) (Fig. 5 and Extended Data
Fig. 2). Genes in the immune related groups were gathered in two
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clusters, in PC3 and PC6−9. Antigen presenting gene expression was
positively associated with co-stimulatory gene expression, not only in
tumor but also in non-cancerous tissue (Extended Data Fig. 2b, c).
Genes involved in the immune response towards endogenous ret-
roviral sequences were also more methylated in adenocarcinoma
compared to SCC, but we did not study the repetitive DNA areas with
high versus low methylation.
2.5. Antigen presenting gene expression in tumor
Average RNA expression of genes in the antigen presenting gene
group was lower in tumor than in non-cancerous tissue and showed a
larger variation (SD) in expression (Fig. 6). HLAA, HLAB and TAP2 RNA
expression showed a decreased density, suggesting suppression of an-
tigen presentation and processing. The other immune related gene
groups in tumors also showed variation, but median values were not
significantly different from non-cancerous tissue. At last, we asked
ourselves what impact the different immune components have on sur-
vival. Interestingly, we were unable to identify survival benefit in an
adjusted Cox regression for high expression of genes involved in antigen
presentation or costimulatory function (Extended Data Table 3). Genes
involved in the inhibition of the immune system also were not asso-
ciated with survival.
3. Discussion
We identified epigenetic and RNA expression patterns in tumor
tissue from NSCLC patients, that distinguished squamous cell lung
cancer from adenocarcinoma. Especially the conserved loci with hardly
variation in DNA methylation between hundreds of patients were re-
sponsible for the distinction between the subtypes. Adenocarcinoma
was globally more methylated than squamous cell carcinoma. Immune
adaptive mechanisms have also been described such as gene hy-
permethylation targeting the interleukin-6/Stat3 pathway [10].
Not only methylation but also the differences in the expression va-
lues of only six genes could explain the difference between the subtypes
in 97 % of patients. Involved genes were keratine 5 (KRT5), tumor
protein p63 (TP63), DSC3, desmoglein 3 (DSG3), calmodulin like 3
(CALML3), and the miRNA MIR205HG. All are directly or indirectly
involved in tissue morphogenesis, differentiation cell adhesion, and
proliferation. The predominant isoform ΔNp63α is overexpressed in
SCC and may influence tissue microenvironment by recruiting proin-
flammatory cells. TP63 is commonly used in immunohistochemistry to
differentiate SCC from adenocarcinoma, which supports the robustness
of our analysis [11–13].
Next, we have shown that immune regulatory genes were included
in regions marked by methylation probes with a ks-score> 95 %; these
methylation profiles were associated with differential expression in
immune modulatory genes before therapy. These genes were located in
methylation regions distinguishing pretreatment NSCLC phenotypes by
distribution, but were not identified by the best split analysis, in-
dicating that genes involved in subtype morphology and immune reg-
ulation are both regulated by methylation but belong to completely
distinct gene groups.
Now we have established the relation between methylation and
immune expression status, we asked ourselves whether the pretreat-
ment expression of the immune modulating gene groups of early NSCLC
patients had survival consequences. We were unable to identify any
Fig. 1. Clustering of main lung cancer phenotypes based on DNA methylation and RNA expression.
A) Pulmonary adenocarcinoma is distinguished from squamous cell carcinoma by DNA methylation and B) to a slightly lesser extent by RNA expression.
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survival benefit. Compared to non-cancerous tissue we observed a much
broader distribution of the expression of immune modulating genes in
NSCLC, while the median expression of T cell co-inhibitory, co-stimu-
latory, and cyto- and chemokine genes remained similar. Only the an-
tigen presenting gene expression in NSCLC was decreased. This group
consisted not only of the classical HLAA, HLAB and HLAC whose ex-
pression depend on methylation but also B2M and TAP genes. By
multiplexed quantitative immunofluorescence loss of expression of
B2M, HLA-I heavy chains and HLA-II was observed in less than 23 % of
NSCLC patients [14]. Loss of B2M expression resulted in decreased or
no cell surface expression of MHC class I, which impairs antigen pre-
sentation to cytotoxic T cells [15,16]. In melanoma loss of B2M and
TAP1 expression reduced overall survival when treated with ipili-
mumab [17]. Limiting the expression of genes involved in antigen
presentation is an important mechanism of tumor cells to evade the
immune system [18]. In early NSCLC tumors that have an activated
immune system, extensive immune editing is present in order to fit with
the tumor microenvironment, as indicated by the relative depletion of
neoantigens in tumors and loss of heterozygosity in HLA genes [19].
This allele-specific HLA loss may occur in about 40 % of NSCLC patients
[18]. We observed that in tumor and non-cancerous tissue antigen
presenting and co-stimulatory gene expression was positively asso-
ciated, suggesting that a higher expression of antigen presenting genes
is associated with more inflammation. Although our analysis does not
provide information on cell types, it suggests that the higher dosage of
antigen presenting gene expression in (any) tissue associates with more
co-stimulatory gene expressions from T cells. Overall, it may be con-
cluded that the antigen presenting gene group harbors the main im-
mune related defect in NSCLC patients.
Finally, our analysis revealed that higher methylation was observed
in genes involved in the immune response towards endogenous retro-
viral sequences in adenocarcinoma compared to SCC. Disruption of
methylation in both subtypes leads to different retroviral expressions.
Moreover, analyzing a wide spectrum of over 2000 involved genes with
the highest subtype separability revealed viral involvement, likely ret-
roviral or transposon loci. As we know, human endogenous retroviruses
are under epigenetic control and rarely expressed in normal tissue
[20,21]. Hypomethylation of the LINE family member L1 occurs in
multiple solid cancers and cell lines [22,23]. Lung squamous cell car-
cinoma has elevated ERVH-5 and other RNA derived endogenous ret-
rovirus expression that were associated with low cytolytic activity [24].
We observed that IRF3, NF-κB and STAT pathways are critical in the
production of type I interferons downstream of pathogen recognition
receptors. They detect viral RNA and DNA [25]. The genes SRPK1 and
TRIM4 are found to regulate these virus-induced IFN induction path-
ways [26,27]. This provides further molecular evidence of the pre-
sumed importance of (retro)viral infection in predominantly squamous
cell carcinoma as previously observed in squamous cell carcinomas that
Fig. 2. Higher DNA methylation in adenocarcinoma compared to squamous cell carcinoma.
A) Adenocarcinoma contains consistently higher methylated DNA than squamous cell lung carcinoma mainly due to a relative small number of probes at conserved
loci compared to B) a theoretical at random model. Overall difference in methylation is 0.017 (positive values on the y-axis indicate higher DNA methylation of
adenocarcinoma, negative values indicate higher DNA methylation of squamous cell carcinoma). X-axis ranks the probes according to the ks-score for differentiation
between both histological subtypes. Y-axis is the difference between the mean methylation (0 is low methylation and 1 is high methylation) between both subtypes.
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contained viral DNA [28]. Importantly, a significant proportion of the
differentiating methylation probes suppresses viral and retroviral as-
sociated genes. Further investigation is needed into the exact nature of
those repetitive areas that are hyper- or hypomethylated.
All studies have limitations. Importantly, the tumor samples have
varying tumor content (at least 40 %) tough, as shown by stratification,
this had no consequences for our findings. In order to perform our
enrichment analysis of the epigenetic background across NSCLC phe-
notypes on a gene level methylation signals were averaged. Although
this approach resulted in relevant and consistent findings, it may lead to
inevitable loss of information as its effect varies across different gene
regions. For instance, hypermethylation of high density CpG regions
has been recognized to strongly associate with gene expression reg-
ulation [29]. Lastly, splicing variants and small cumulative effects
within several genes in the same pathway have not taken into con-
sideration in the RNA expression analysis. Alternative splicing may
have a functional impact and is increased in cancer compared to normal
tissue [29].
Together these results show that NSCLC phenotypes are largely
determined by epigenetic regulation of a small conserved group of
genes, involved in extracellular matrix and cell structure. Methylation
controls immune related genes – also those involved in endogenous
retroviral sequences - that show a larger expression diversity in tumor
than in non-cancerous tissue. Decreased expression of genes involved in
antigen presentation are the main immune related defect in NSCLC,
highlighting their importance for immune invasion by the tumor.
4. Methods
4.1. Study cohort and data acquisition
Patients with treatment naive NSCLC, adenocarcinoma and SCC,
whose DNA methylation and RNA expression data from the resected
tumor was available in the public domain, were selected from two
different profiling platforms (RNA sequencing resulting in 60,483
mRNA expression values and methylation profiling by Infinium HM450
platform resulting in 485,577 DNA methylation β-values) at the TCGA
Research Network (http://cancergenome.nih.gov/). Details on methods
and data generation of the RNA sequencing and DNA methylation can
be found in the original TCGA landmark papers [3,4] Duplicate
Fig. 3. Location of methylation probes along 23 chromosomes that separates adenocarcinoma from squamous cell lung carcinoma at ks ≥ 0.95 and ks ≥ 0.97 level.
Methylation pattern for each chromosome characterized by their individual probes A) with ks-score for separability between histologic subtypes over 95 % are evenly
distributed over chromosomes with an exception for the x-chromosome. B) Probes with ks-score over 97 % show the conserved methylated areas that preserve the
difference between subtypes. Mostly they are related to CpG islands located along chromosomes. X-axis and y-axis refer to respectively the chromosome number and
individual probe localization on the chromosome according to ks-score for separability. Green dots represent differential probes. Antigen presentation and costi-
mulation genes are flagged for chromosome location. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of
this article).
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samples, those with missing histological diagnosis, and those with
disease recurrences were removed. In total, 1024 unique NSCLC pa-
tients with tumor tissue were selected of whom 154 patients provided
additional normal tissue. Patients with normal tissue provided 108
samples for the normal RNA expression dataset and 74 samples for the
normal DNA methylation dataset; 28 patients provided samples for both
methods. The tumor RNA expression dataset consisted of 1014 tumor
samples (513 adenocarcinoma and 501 SCC) and the tumor methyla-
tion dataset consisted of 828 tumor samples (458 adenocarcinoma and
370 SCC). We extracted clinical and pathological data on age, gender,
histology, stage of disease, tumor cell percentage and survival calcu-
lated from time of diagnosis to time of death or last follow-up (Extended
Fig. 4. Relation between DNA methylation for immune modulating genes determined by one probe and gene expression at four quartile levels.
A) Immune modulating genes identified by probes with ks-score ≥ 70 % (adenocarcinoma vs. SCC) show an inverse relationship between expression and methylation
for most genes. In this example, LAG3 and B3GAT1 show the opposite expression effect at low and moderate methylation, respectively. Examples are shown of probes
with B) the highest negative correlation, C) highest positive correlation and D) no correlation between DNA methylation and RNA expression. E) The percentage of
methylation probes that are inversely correlated with RNA expression depends on the cut-off of the correlation between methylation and gene expression of a probe
and minimal average methylation.
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Data Table 4). The dataset was analyzed during a hackathon session, in
which data scientists in collaboration with physicians competed to
create a “functioning” product by the end of the 3-day event.
4.2. Data curation and statistical methods
All datasets were filtered and curated for non-significantly asso-
ciated features after preprocessing of the files. ComBat, an empirical
Bayes location/scaling method was applied to rule out potential cohort
bias in the RNA expression data as a consequence of different study sites
and laboratories, whereas BEclear was used in the DNA methylation
data (Supplementary Information). As co-variant we used gender, be-
cause this factor has a high variance over the batches and its value is
known for all samples. We started with principal component analysis
(PCA) to discern underlying structure of the database, e.g. the total
gene expression versus the immune modulating gene groups expres-
sions.
For RNA expression and DNA methylation data we used non-para-
metric tests. The separation of the cancer types was compared before
and after bias correction with both the Kolmogorov-Smirnov test and
Mann-Whitney U test The Kolmogorov-Smirnov tests provides a ks-
score, which determines whether the given distributions of two groups
are the same or different with a probability of 1-ks-score
(Supplementary Information). After we determined differences in dis-
tributions of methylation probes, an algorithm was developed using
separate cut-off values for DNA methylation and RNA expression to
identify the most predictive genes to classify the NSCLC subtypes. This
best split analysis determined whether a cut-off value could provide a
split of at least 85 % of patients into the correct subtype with a certainty
of more than 80 %, starting with probes or genes that had the highest
differences (fold change). Differences between tumor subtypes based on
DNA methylation β value had to be at least 0.1 to increase the prob-
ability of biological relevance. Loci with the largest differences for both
DNA methylation and RNA expression respectively were determined
after the annotating the probes into corresponding genes, an overlap in
genes of both lists was established for biological interpretation.
Different immune modulatory genes were selected and grouped
according to their function (Extended Data Table 5). These include co-
stimulatory genes (COSTIM), co-inhibitory genes (COINHIB), antigen
presenting genes (AGPRES) and immune modulatory/ inflammatory
cytokines and chemokines (CYTCHEM). The co-stimulatory immune
modulatory gene group included genes that are known to be expressed
in tumor cells (e.g. ICOSL, OX40 L, SLAM), as reviewed by Chen and
Flies [30]. Similarly, co-inhibitory genes were included in the analysis
(e.g. VTCN1, CD113, CD48). HLAE was included for its protein function
as inhibitor ligand for immunocompetent (NK) cells [31,32]. For an-
tigen presentation, genes were selected involved in antigen presenta-
tion (e.g. classical HLA) and genes involved in antigen processing (e.g.
TAP1, CIITA, HLAA) were selected for inclusion in the antigen pre-
sentation genes group [33]. Genes coding for cytokines and chemokines
(e.g. IL10, IDO, IFNG) were selected based on their implication in im-
mune tolerance of cancer through pleiotropic effects in immune reg-
ulation and inflammation [34–36].
Gene densities of all AGPRES genes were calculated within R using a
kernel density estimate from the distribution of RNA expression of
NSCLC and non-cancerous tissue.
To study the relationship between expression of immune related
gene groups (AGPRES, COSTIM, COINHIB, CYTCHEM) and overall
survival, a multivariate Cox regression analysis was used with age,
gender, smoking (pack years), tumor type and stage of disease as cov-
ariates (patient factors with p<0.1 from univariate analysis included).
The expression of pretreatment immune related gene groups was used
as a categorical variable with two levels divided by the median (high
and low overall expression of all involved genes). Hazard ratios (HR)
and 95 % confidence intervals (CI) are reported.
To investigate the biological pathways, Ingenuity Pathway Analysis
(Qiagen, Hilden, Germany) was used to perform gene enrichment
analyses on these gene lists.
Transparency document
The Transparency document associated with this article can be
found in the online version.
Fig. 5. Four immune modulatory gene groups as
compared with all gene expressions in non-small cell
lung cancers shows two clusters of increase (PC3 and
PC6-9).
Four main immune modulatory gene groups were
distinguished, involved in T cell antigen presentation
(AGPRES), T cell co-inhibitory (COINHIB), T cell co-
stimulator (COSTIM) and T cell cytokines/chemokines
(CYTOCHEM). The influence of these gene groups
were investigated on the individual principle compo-
nents. The y-axis represents the loading of a gene in
the DNA expression dataset to a principle component.
The red boxes indicate all genes in the DNA expression
dataset, whereas the other boxes represent the genes of
selected immune modulating gene groups. All immune
modulating gene groups are most pronounced in PC7,
PC8 and PC9. The midline in the boxplot is the median
of data in that component, with the lower and upper
limits of the box being the first and third quartile, re-
spectively. By default, the whiskers will extend up to
1.5 times the interquartile range from the top (bottom)
of the box. If there are any data beyond that distance,
they are represented individually as black dots ('out-
liers'). (For interpretation of the references to colour in
this figure legend, the reader is referred to the web
version of this article).
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